Patents on Natural Products for Diagnosing/Preventing/Treating Alzheimer's Disease

Abstract The chapter describes patent and patent applications on natural products for diagnosing, preventing and treating Alzheimer's disease. The chapter briefly discusses overview, existing approaches and strategies for Alzheimer's disease. Specifically, the chapter describes patent and patent applications on natural products in terms of the discovery, isolation, extraction, synthesis and uses of compounds, compositions, extracts for diagnosing, preventing and treating Alzheimer's disease. Further, the chapter illustrates patented procedures for isolation and extraction of natural products. Furthermore, the chapter focuses on patented procedures for synthesizing natural products. Additionally, the chapter discloses patent and patent applications exhibiting the uses of compounds and compositions of natural products for diagnosing, preventing and treating Alzheimer's disease. In addition, the chapter demonstrates patent and patent applications displaying uses of plant extracts for diagnosing, preventing and treating Alzheimer's disease.

[1]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[2]  R. W. Sabnis.  Handbook of Acid-Base Indicators , 2007 .

[3]  F. Barrantes,et al.  Neuronal nicotinic acetylcholine receptor–cholesterol crosstalk in Alzheimer's disease , 2010, FEBS letters.

[4]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[5]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[6]  E. Mandelkow,et al.  Progress and developments in tau aggregation inhibitors for Alzheimer disease. , 2013, Journal of medicinal chemistry.

[7]  M. Rosini,et al.  Curcumin in Alzheimer's disease: Can we think to new strategies and perspectives for this molecule? , 2017, Pharmacological research.

[8]  Robert W Berry,et al.  Tau, tangles, and Alzheimer's disease. , 2005, Biochimica et biophysica acta.

[9]  Ramesh Kandimalla,et al.  Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[10]  Chih-ping Chen,et al.  Curcuminoids and resveratrol as anti-Alzheimer agents. , 2012, Taiwanese journal of obstetrics & gynecology.

[11]  Korey Kam,et al.  Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer’s disease , 2016, Sleep medicine reviews.

[12]  E. Andrási,et al.  Disturbances of magnesium concentrations in various brain areas in Alzheimer's disease. , 2000, Magnesium research.

[13]  Puneet Kumar,et al.  Alzheimer's disease: Is this a brain specific diabetic condition? , 2016, Physiology & Behavior.

[14]  I. Hamley.  The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. , 2012, Chemical reviews.

[15]  Wei⁃qin Zhao,et al.  Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. , 2009, Biochimica et biophysica acta.

[16]  T. Anekonda.  Resveratrol—A boon for treating Alzheimer's disease? , 2006, Brain Research Reviews.

[17]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[18]  Aslı Ece Çilliler,et al.  Serum Magnesium Level and Clinical Deterioration in Alzheimer’s Disease , 2007, Gerontology.

[19]  Scott A. Small,et al.  Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis , 2008, Neuron.

[20]  Laure Peter-Derex,et al.  Sleep and Alzheimer's disease. , 2015, Sleep medicine reviews.

[21]  J. Glick.  Dementias: the role of magnesium deficiency and an hypothesis concerning the pathogenesis of Alzheimer's disease. , 1990, Medical hypotheses.

[22]  N. Delibaş,et al.  Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. , 2010, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[23]  P. Reddy,et al.  Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. , 2017, Drug discovery today.

[24]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[25]  M. Bursavich,et al.  Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon? , 2016, Journal of medicinal chemistry.

[26]  Guojun Bu,et al.  ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners? , 2014, Neuron.

[27]  C. Kawas,et al.  Late-Onset Alzheimer Disease. , 2017, Neurologic clinics.

[28]  C. Troakes,et al.  Aluminium in brain tissue in familial Alzheimer's disease. , 2017, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

[29]  G. Lees,et al.  Zinc and Alzheimer's disease: is there a direct link? , 1997, Brain Research Reviews.

[30]  D. Butterfield,et al.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. , 2014, Biochimica et biophysica acta.

[31]  L. Mucke,et al.  100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.